계명대학교 의학도서관 Repository

Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04)

Metadata Downloads
Author(s)
Sung Uk LeeJinsil SeongTae Hyun KimJung Ho ImWoo Chul KimKyubo KimHae Jin ParkTae Gyu KimYoungkyong KimBae Kwon JeongJin Hee KimByoung Hyuck KimTaek-Keun Nam
Keimyung Author(s)
Kim, Jin Hee
Department
Dept. of Radiation Oncology (방사선종양학)
Journal Title
Cancer Biol Med
Issued Date
2022
Volume
19
Issue
6
Keyword
Gallbladder canceradjuvant treatmentchemoradiotherapylocoregional recurrence-free survivaloverall survival
Abstract
Objective:
The effectiveness of adjuvant treatments for resected gallbladder carcinoma (GBC) has remained unclear due to lack of randomized controlled trials; thus, the aim of present study was to evaluate the role of adjuvant treatments, including chemoradiotherapy (CRT) and/or chemotherapy (CTx), in patients with resected GBC.

Methods:
A total of 733 GBC patients who received curative-intent surgical resection were identified in a multi-institutional database. Of 733 patients, 372 (50.8%) did not receive adjuvant treatment, whereas 215 (29.3%) and 146 (19.9%) received adjuvant CTx and CRT, respectively. The locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS), and overall survival (OS) of the adjuvant treatment groups were compared according to tumor stage (stage II vs. stage III-IV).

Results:
In stage II disease (n = 381), the 5-year LRFS, RFS, and OS were not significantly different among the no-adjuvant therapy, CTx, and CRT groups, and positive resection margin, presence of perineural invasion, and Nx classification were consistently associated with worse LRFS, RFS, and OS in the multivariate analysis (P < 0.05). For stage III-IV (n = 352), the CRT group had significantly higher 5-year LRFS, RFS, and OS than the no-adjuvant therapy and CTx groups (67.8%, 45.2%, and 56.9%; 37.9%, 28.8%, and 35.4%; and 45.0%, 30.0%, and 45.7%, respectively) (P < 0.05).

Conclusions:
CRT has value as adjuvant treatment for resected GBC with stage III-IV disease. Further study is needed for stage II disease with high-risk features.
Keimyung Author(s)(Kor)
김진희
Publisher
School of Medicine (의과대학)
Citation
Sung Uk Lee et al. (2022). Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04). Cancer Biol Med, 19(6), 931–944. doi: 10.20892/j.issn.2095-3941.2020.0667
Type
Article
ISSN
2095-3941
Source
https://www.cancerbiomed.org/content/19/6/931
DOI
10.20892/j.issn.2095-3941.2020.0667
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/44272
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.